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Abstract Patients with heart failure used to have an
increased risk of stroke, but this may have changed with
current treatment regimens. We assessed the association
between heart failure and the risk of stroke in a population-
based cohort that was followed since 1990. The study uses
the cohort of the Rotterdam Study and is based on 7,546
participants who at baseline (1990–1993) were aged
55 years or over and free from stroke. The associations
between heart failure and risk of stroke were assessed using
time-dependent Cox proportional hazards models, adjusted
for cardiovascular risk factors (smoking, diabetes mellitus,
BMI, ankle brachial index, blood pressure, atrial fibrilla-
tion, myocardial infarction and relevant medication). At
baseline, 233 participants had heart failure. During an
average follow-up time of 9.7 years, 1,014 persons devel-
oped heart failure, and 827 strokes (470 ischemic, 75
hemorrhagic, 282 unclassified) occurred. The risk of
ischemic stroke was more than five-fold increased in the
first month after diagnosis of heart failure (age and sex
adjusted HR 5.79, 95% CI 2.15–15.62), but attenuated over
time (age and sex adjusted HR 3.50 [95% CI 1.96–6.25]
after 1–6 months and 0.83 [95% CI 0.53–1.29] after
0.5–6 years). Additional adjustment for cardiovascular
risk factors only marginally attenuated these risks. In
conclusion, the risk of ischemic stroke is strongly increased
shortly after the diagnosis of heart failure but returns to
normal within 6 months after onset of heart failure.
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Introduction
Almost one out of three persons of 55 year and over will
develop heart failure during their remaining lifespan [1–5].
Because of its high incidence, heart failure may have an
important impact on the incidence of other diseases,
including stroke [6].
Previous studies found that the risk of stroke among heart
failure patients is almost 7 times higher than in the general
population [7–13]. However, most population-based studies
were performed before the 1990s when ACE inhibitors
were introduced on a large scale. Current guidelines rec-
ommend the use of ACE inhibitors in all patients with
symptomatic systolic heart failure [14]. The survival rate of
heart failure has improved significantly over the past dec-
ades, and also the risk of stroke in heart failure patients was
higher in studies performed before 1990 than in more recent
ones [9, 15]. This makes it hard to extrapolate findings from
previous population-based studies to the present day; in
addition, most previous studies did not adjust for con-
founders other than age and sex [8, 11, 12, 16]. In 2006,
Witt et al. found a 17.4-fold increased risk of stroke in the
fist 30 days after heart failure diagnosis, which was reduced
to 2.9-fold after 5 years [16]. This suggests that the risk of
stroke varies with time after the diagnosis of heart failure.
We investigated the association between heart failure
and the risk of stroke in a large prospective population-
based cohort study that started in 1990. To compare our
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results with previous studies, which almost invariably
focused on the short-term prognosis of heart failure, we
also wished to investigate the longer term-prognosis of
heart failure and assessed the risk of stroke in various time
intervals after the diagnosis of heart failure.
Methods
Population
The present study is part of the Rotterdam Study, a popu-
lation-based prospective cohort study on chronic and dis-
abling diseases. All inhabitants of Ommoord, a district in
the city of Rotterdam in the Netherlands, who were
55 years or older were invited to participate. Of all 10,275
invited subjects, 7,983 were entered into the study (78%)
[17]. The Medical Ethics Committee of the Erasmus
Medical Center approved the study. Baseline examinations,
which consisted of a home interview and clinical workup at
the research center, were conducted between 1990 and
1993. Subsequently, participants were continuously moni-
tored for major events, including stroke and heart failure,
through automated linkage of the study database with files
from general practitioners. Information on vital status is
obtained regularly from municipal health authorities in
Rotterdam. Furthermore, all drug prescriptions dispensed
to participants by all pharmacies in the study area are
routinely stored in the database. After exclusion of par-
ticipants who refused informed consent (n = 174), partic-
ipants with missing data (n = 20), or who had a stroke
before baseline (n = 243), 7,546 persons were included in
this study.
Assessment of heart failure
Prevalent heart failure at baseline was assessed using a
validated score, that was based on the heart failure defi-
nition of the European Society of Cardiology [18]. More
details of the assessment have been described previously
[1, 19]. Prevalent heart failure cases were obtained through
a database containing hospital discharge diagnoses from all
hospitals in the Rotterdam area as of January 1, 1991 [20].
Furthermore, all medical records were screened in retro-
spect for the occurrence of heart failure in most (97%)
participants of the Rotterdam Study. With these three
methods, information on the presence of heart failure at
baseline was available for all participants.
Cases of incident heart failure were obtained by con-
tinuously monitoring participants of the Rotterdam Study
for the occurrence of heart failure during follow-up through
automated linkage with files from general practitioners.
Also, we used verified hospital discharge diagnoses for
case finding, gathered from all hospitals in the Rotterdam
area. The date of incident heart failure was defined as the
day of the first occurrence of symptoms suggestive of heart
failure, obtained from the medical records, or the day of
receipt of a first prescription for a loop diuretic or an ACE-
inhibitor indicated for treatment of heart failure, whichever
came first.
The diagnosis of heart failure was classified as definite,
probable, possible, or unlikely. Only definite and probable
cases were considered in the analyses. In accordance with
the criteria of the European Society of Cardiology, definite
heart failure was defined as a combination of heart failure
diagnosed by a medical specialist and the presence of
typical symptoms of heart failure, such as breathlessness at
rest or during exertion, ankle edema, and pulmonary cre-
pitations, confirmed by objective evidence of cardiac dys-
function (chest X-ray, echocardiography) [18]. Probable
heart failure was defined as heart failure diagnosed by a
general practitioner, with at least two typical symptoms
suggestive of heart failure, and at least 1 of the following:
history of cardiovascular disease, response to treatment of
heart failure, or objective evidence of cardiac dysfunction,
whereas symptoms could not be attributed to another
underlying disease.
Two research physicians independently classified all
information on potential heart failure events. If there was
disagreement, a consensus was reached in a separate ses-
sion. Finally, a cardiologist verified all probable cases, and
all cases in which the two physicians could not reach
consensus. If the cardiologist disagreed with the research
physicians, the cardiologist’s judgment was considered
decisive.
Assessment of stroke
History of stroke at baseline was assessed and verified as
described previously [21]. In summary, during the baseline
interview, a previous stroke was assessed by asking, ‘‘Did
you ever suffer from a stroke, diagnosed by a physician?’’
Medical records of patients who answered yes were
checked to verify the diagnosis [22, 23]. Once subjects are
enrolled in the Rotterdam Study, they are monitored con-
tinuously for major events through automated linkage of
the study database with files from general practitioners and
the municipality. In addition, nursing home physicians’
files are scrutinized. For reported events, additional infor-
mation (including brain imaging) is obtained from hospi-
tals. Stroke research physicians reviewed information on
all possible strokes; an experienced stroke neurologist
(P.J.K.) verified all diagnoses.
Ischemic strokes were diagnosed when a patient had
typical symptoms and a CT or MRI within 4 weeks that
ruled out other diagnoses or when indirect evidence (deficit
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limited to 1 limb or completely resolved within 72 h, atrial
fibrillation in the absence of anticoagulants) pointed at an
ischemic nature of the stroke. Hemorrhagic stroke was
diagnosed when a relevant hemorrhage was shown on CT
or MRI. If a stroke did not match any of these criteria, it
was classified as unspecified.
Possible confounders
Blood pressure was measured twice in sitting position on
the right arm with a random-zero sphygmomanometer. We
used the average of these measurements. A single systolic
blood pressure reading was taken at both the left and the
right posterior tibial arteries with a Doppler ultrasound
8 MHz transducer while the subject was in the supine
position. Ankle-Brachial index was calculated by dividing
tibial blood pressure by brachial blood pressure. We con-
sidered diabetes mellitus to be present if a random or
postload glucose level was more than 11.0 mmol/l or if a
person used antidiabetic medication. Quetelet body mass
index (calculated as weight in kilograms divided by the
square of height in meters) was assessed at the research
center. During the home interview, smoking status (clas-
sified as ever or never) and medication use were assessed.
Occurrence of myocardial infarction and atrial fibrillation
before baseline and during follow-up was assessed and
verified as described previously [24, 25].
Statistical analysis
We calculated hazard ratios with 95% confidence intervals
(95% CIs) for the associations between heart failure and
the risk of stroke, with Cox proportional hazards models.
Hazard ratios were calculated for any stroke, ischemic
stroke, and hemorrhagic stroke. Furthermore, we assessed
whether the association between heart failure and risk of
stroke was different in various time intervals (0–30 days,
30 days to 6 months and 6 months to 5 years) after the
diagnosis of heart failure. For the 30 days to 6 months
period and 6 months to 5 years period, the time between
diagnosis of heart failure and start of the period of interest
was not counted as person-time at risk. We only used first-
ever strokes. Subjects were censored at the time of death,
end of study or, in case of loss to follow-up, at the date last
known to be alive. Follow-up was complete for all par-
ticipants until January 1, 2005, for 97.1% of potential
person years [26].
All hazard ratios were adjusted for age and sex (model
A) and additionally for smoking, diabetes mellitus, BMI,
ankle-brachial index, systolic blood pressure, use of anti-
hypertensive drugs, use of antithrombotic drugs and for
occurrence of atrial fibrillation and myocardial infarction
before baseline and during follow-up (model B) [27–31].
Heart failure, systolic blood pressure, BMI, diabetes mel-
litus, atrial fibrillation and myocardial infarction were
entered as time-dependent covariates. We had \1% mis-
sings for all variables during the baseline examination
except for blood pressure (n = 799), ankle brachial index
(n = 1,343) and BMI (n = 858). Mean values were
imputed to missing values for blood pressure, ankle bra-
chial index and BMI. Analyses were performed using SPSS
11.0.1 for Windows.
Results
At baseline, the median age of the study population was
69 years. Of all 7,546 participants, 4,596 were female and
233 had heart failure (baseline characteristics are presented
in Table 1). During 73,147 person years of follow-up, 827
first-ever strokes occurred. Of all strokes, 470 were
ischemic, 75 hemorrhagic, and 282 could not be specified.
Additionally, 1,014 participants developed heart failure.
Participants with heart failure had a higher risk of sub-
sequent stroke than participants without heart failure
(Table 2) with no significant differences between men and
women (P interaction = 0.69). When adjusted for cardio-
vascular risk factors, this association disappeared (HR
1.07, 95% CI 0.86–1.32; model B). For ischemic strokes,
the age and sex adjusted hazard ratio was 1.51 (95% CI
1.15–1.98), which disappeared after adjustment for possi-
ble cardiovascular risk factors (HR 1.02, 95% CI
0.77–1.37). In particular the inclusion of atrial fibrillation
in model B caused the association to disappear. Heart
failure was not associated with the risk of hemorrhagic
stroke (age and sex adjusted HR 1.02, 95% CI 0.49–2.16).
The risk of stroke was highest in the first 30 days after the
diagnosis of heart failure (age and sex-adjusted HR 4.27
(95% CI 1.90–9.60) for stroke, HR 5.79, (95% CI 2.15
Table 1 Baseline characteristics of the study population (n = 7,546)
Characteristic Median (interquartile range)
or number (percentage)
Age (years) 69.0 (62.3–76.7)
Female sex 4,596 (60.9%)
Ever smoking 4,649 (61.6%)
Diabetes mellitus 756 (10.0%)
Body mass index (kg/m2) 26.3 (24.1–28.0)
Systolic blood pressure (mmHg) 139 (125–152)
Ankle brachial index 1.05 (1.00–1.18)
Antihypertensive drug use 2,466 (32.7%)
ACE-inhibitor use 466 (6.2%)
Antithrombotic drug use 369 (4.9%)
Heart failure (at baseline) 233 (3.1%)
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15.62) for ischemic stroke (Table 3) and decreased signifi-
cantly with increasing time since first diagnosis of heart fail-
ure: P for interaction between time since diagnosis and heart
failure, 0.004 for stroke, and 0.003 for ischemic stroke. The
risk remained increased during the first half year after diag-
nosis of heart failure (Table 3), but was no longer increased
thereafter. Adjustments for cardiovascular risk factors (model
B) modestly attenuated these hazard ratios, and showed a
decreased risk of ischemic stroke after 0.5–6 years (age and
sex adjusted HR 0.58, 95% CI 0.37–0.92).
Discussion
Men and women with heart failure had a higher risk of
stroke than those without heart failure in this population-
based cohort study. The risk of stroke was more than four-
fold increased during the month following the diagnosis of
heart failure, but had returned to normal by the time people
had survived 6 months after the diagnosis of heart failure.
Strengths of our study are its population-based design, the
large study population (N = 7,546), a mean follow-up of
approximately 10 years, and the meticulous ascertainment
of heart failure and stroke cases. The follow-up of our cohort
started in 1990, so after the introduction of current treatment
regimens for heart failure. Our stringent stroke monitoring
procedures enabled the ascertainment of stroke cases that
had not been referred to a hospital and hence would have
been missed had we only relied on hospital records, as is the
case in many cohort studies. However, since in these non-
hospitalized patients neuroimaging was lacking, 34% of all
strokes could not be subclassified into ischemic or hemor-
rhagic. Although we adjusted for potential cardiovascular
confounders, residual confounding may remain.
Several previous studies reported an increased risk of
stroke shortly after the diagnosis of heart failure [7, 8, 10,
16]. Most of these studies had a short follow-up of several
months, did not adjust for confounders other than age and
sex or were based on hospitalized patients only [7, 8, 10].
In 2006, a study from Rochester followed 630 persons with
incident heart failure for a longer period (median follow-up
4.3 years) and reported a 17.4-fold increased risk of stroke
in the first 30 days after heart failure diagnosis, which
decreased to 2.9-fold after 5 years [16]. In line with the
earlier studies we found a 4.3-fold increase for the risk of
stroke in the first month after diagnosis of heart failure and
Table 2 Hazard ratios and 95% CIs for the associations between heart failure and risk of subsequent stroke
Hazard ratio (95% CI)
All stroke Ischemic stroke Hemorrhagic stroke
Presence of heart failure (n = 827) (n = 470) (n = 75)
No heart failure (N = 6,299) 1 (reference) 1 (reference) 1 (reference)
Heart failure (N = 1,247) Model A 1.41 (1.15–1.72) 1.51 (1.15–1.98) 1.02 (0.49–2.16)
Model B 1.07 (0.86–1.32) 1.02 (0.77–1.37) 0.80 (0.37–1.76)
Model A: Adjusted for age and sex
Model B: Adjusted for age, sex, smoking, diabetes mellitus, BMI, ankle-brachial index, blood pressure, use of antihypertensives, use of
antithrombotics, incident and prevalent atrial fibrillation and incident and prevalent myocardial infarction
Table 3 Hazard ratios and 95% CIs for the association between heart failure and the risk of subsequent stroke and ischemic stroke for various
time intervals after the diagnosis of heart failure
Outcome Presence of heart failure Hazard ratio (95% CI)
0–30 days 30 days–6 months 6 months–5 years
All stroke No heart failure (N = 6299, 749 strokes) 1 (reference) 1 (reference) 1 (reference)
Heart failure (N = 1247, 78 strokes)* Model A 4.27 (1.90–9.60) 1.94 (1.14–3.31) 0.99 (0.74–1.33)
Model B 3.59 (1.59–8.10) 1.60 (0.93–2.73) 0.78 (0.58–1.05)
Ischemic stroke No heart failure (N = 6299, 428 ischemic strokes) 1 (reference) 1 (reference) 1 (reference)
Heart failure (N = 1247, 42 ischemic strokes)* Model A 5.79 (2.15-15.62) 3.50 (1.96-6.25) 0.83 (0.53-1.29)
Model B 4.60 (1.70-12.49) 2.75 (1.53-4.94) 0.58 (0.37-0.92)
Model A: Adjusted for age and sex
Model B: Adjusted for age, sex, smoking, diabetes mellitus, BMI, ankle-brachial index, blood pressure, use of antihypertensives, use of
antithrombotics, incident and prevalent atrial fibrillation and incident and prevalent myocardial infarction
* 11 strokes, of which 7 ischemic, occurred between 0 and 30 days after the diagnosis of heart failure, 15 strokes of which 12 ischemic, between
30 days and 6 months, and 52 strokes, of which 23 ischemic, between 6 months and 5 years
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an almost six-fold increased risk for ischemic stroke in this
period, that only slightly attenuated when adjusted for
cardiovascular risk factors. However, in our study these
increased risks returned to normal within 6 months after
onset of heart failure, and the risk of ischemic stroke was
even slightly decreased after 0.5–5 years after the diag-
nosis of heart failure. This is either a chance finding or may
possibly be explained by competing risk or medication
effect. A possible explanation for the discrepant findings
between our study and the study from Rochester is that our
patients developed heart failure after 1991 and most of
them were treated with ACE inhibitors, whereas the
inclusion period of the Rochester study was stretched over
20 years, from 1979 till 1999, and many persons did not
receive current standard treatment.
Heart failure may cause stroke through cardioembolism.
Due to the increased risk of stroke in heart failure patients,
these persons might benefit from antithrombotic treatment,
in particular during the first month after heart failure
diagnosis. Currently, a large trial is being undertaken to
examine the effect of antithrombotic therapy in patients
with heart failure, but this trial assesses the 3–5 year sur-
vival while ignoring the first month after heart failure [32,
33]. With an increased risk of stroke after heart failure, and
in particular in the first month after onset of heart failure,
our results suggest that this study may miss an important
window of opportunity to prevent stroke in persons with
recent heart failure.
In conclusion, the risk of stroke is strongly increased in
the early phase after the diagnosis of heart failure and
attenuates over time. Investigating whether a more rigorous
treatment of newly diagnosed heart failure patients may
result in a decreased incidence of stroke is warranted.
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